HLA class I antigen processing machinery defects in antitumor immunity and immunotherapy

Ferrington, 2012, Immunoproteasomes: structure, function, and antigen presentation, Prog. Mol. Biol. Transl. Sci., 109, 75, 10.1016/B978-0-12-397863-9.00003-1

Saveanu, 2005, Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum, Nat. Immunol., 6, 689, 10.1038/ni1208

Blees, 2017, Structure of the human MHC-I peptide-loading complex, Nature, 551, 525, 10.1038/nature24627

Montealegre, 2018, Endocytic recycling of MHC class I molecules in non-professional antigen presenting and dendritic cells, Front. Immunol., 9, 3098, 10.3389/fimmu.2018.03098

Weigert, 2004, Rab22a regulates the recycling of membrane proteins internalized independently of clathrin, Mol. Biol. Cell, 15, 3758, 10.1091/mbc.e04-04-0342

Cai, 2018, Defective HLA class I antigen processing machinery in cancer, Cancer Immunol. Immunother., 67, 999, 10.1007/s00262-018-2131-2

Seliger, 2020, HLA class I antigen processing machinery defects in cancer cells – frequency, functional significance, and clinical relevance with special emphasis on their role in T cell-based immunotherapy of malignant disease, Methods Mol. Biol., 2055, 325, 10.1007/978-1-4939-9773-2_15

Cai, 2017, HLA class I antigen-processing machinery in cancer, 44

Maleno, 2011, Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors, Immunogenetics, 63, 65, 10.1007/s00251-010-0494-4

Sucker, 2014, Genetic evolution of T-cell resistance in the course of melanoma progression, Clin. Cancer Res., 20, 6593, 10.1158/1078-0432.CCR-14-0567

Zhao, 2016, Melanoma lesions independently acquire T-cell resistance during metastatic latency, Cancer Res., 76, 4347, 10.1158/0008-5472.CAN-16-0008

Ozcan, 2018, Complex pattern of immune evasion in MSI colorectal cancer, Oncoimmunology, 7, 10.1080/2162402X.2018.1445453

Van Allen, 2015, Genomic correlates of response to CTLA-4 blockade in metastatic melanoma, Science, 350, 207, 10.1126/science.aad0095

Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348

Samstein, 2019, Tumor mutational load predicts survival after immunotherapy across multiple cancer types, Nat. Genet., 51, 202, 10.1038/s41588-018-0312-8

Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N. Engl. J. Med., 371, 2189, 10.1056/NEJMoa1406498

Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N. Engl. J. Med., 375, 819, 10.1056/NEJMoa1604958

Sade-Feldman, 2017, Resistance to checkpoint blockade therapy through inactivation of antigen presentation, Nat. Commun., 8, 1136, 10.1038/s41467-017-01062-w

Chowell, 2018, Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy, Science, 359, 582, 10.1126/science.aao4572

Gettinger, 2017, Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer, Cancer Discov., 7, 1420, 10.1158/2159-8290.CD-17-0593

Florea, 2018, Epigenetic changes of the immune system with role in tumor development, Methods Mol. Biol., 1856, 203, 10.1007/978-1-4939-8751-1_11

Jongsma, 2019, The regulatory network behind MHC class I expression, Mol. Immunol., 113, 16, 10.1016/j.molimm.2017.12.005

van den Elsen, 2011, Expression regulation of major histocompatibility complex class I and class II encoding genes, Front. Immunol., 2, 48, 10.3389/fimmu.2011.00048

Gobin, 1998, The role of enhancer A in the locus-specific transactivation of classical and nonclassical HLA class I genes by nuclear factor kappa B, J. Immunol., 161, 2276, 10.4049/jimmunol.161.5.2276

Meissner, 2010, NLR family member NLRC5 is a transcriptional regulator of MHC class I genes, Proc. Natl. Acad. Sci. U. S. A., 107, 13794, 10.1073/pnas.1008684107

Bukur, 2010, Identification of E2F1 as an important transcription factor for the regulation of tapasin expression, J. Biol. Chem., 285, 30419, 10.1074/jbc.M109.094284

Chang, 2015, Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy, J. Biol. Chem., 290, 26562, 10.1074/jbc.M115.676130

Nie, 2001, DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas, Carcinogenesis, 22, 1615, 10.1093/carcin/22.10.1615

Fonsatti, 2003, Methylation-regulated expression of HLA class I antigens in melanoma, Int. J. Cancer, 105, 430, 10.1002/ijc.11077

Serrano, 2001, Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′-deoxycytidine treatment, Int. J. Cancer, 94, 243, 10.1002/ijc.1452

Fonsatti, 2007, Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2′-deoxycytidine in cutaneous melanoma: immunotherapeutic implications, Clin. Cancer Res., 13, 3333, 10.1158/1078-0432.CCR-06-3091

Burr, 2019, An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer, Cancer Cell, 36, 385, 10.1016/j.ccell.2019.08.008

Kim, 2016, Targeting EZH2 in cancer, Nat. Med., 22, 128, 10.1038/nm.4036

Zhou, 2020, Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer, Clin. Cancer Res., 26, 290, 10.1158/1078-0432.CCR-19-1351

Gameiro, 2016, Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells, Oncotarget, 7, 7390, 10.18632/oncotarget.7180

Ritter, 2017, Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma, Sci. Rep., 7, 10.1038/s41598-017-02608-0

Görisch, 2005, Histone acetylation increases chromatin accessibility, J. Cell Sci., 118, 5825, 10.1242/jcs.02689

Ugurel, 2019, MHC class-I downregulation in PD-1/PD-L1 inhibitor refractory Merkel cell carcinoma and its potential reversal by histone deacetylase inhibition: a case series, Cancer Immunol. Immunother., 68, 983, 10.1007/s00262-019-02341-9

Topper, 2020, The emerging role of epigenetic therapeutics in immuno-oncology, Nat. Rev. Clin. Oncol., 17, 75, 10.1038/s41571-019-0266-5

Ghoneim, 2017, De novo epigenetic programs inhibit PD-1 blockade-mediated T cell rejuvenation, Cell, 170, 142, 10.1016/j.cell.2017.06.007

Morera, 2016, Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy, Clin. Epigenetics, 8, 57, 10.1186/s13148-016-0223-4

Girdlestone, 1995, Regulation of HLA class I loci by interferons, Immunobiology, 193, 10.1016/S0171-2985(11)80548-6

Meissner, 2010, NLR family member NLRC5 is a transcriptional regulator of MHC class I genes, Proc. Natl. Acad. Sci. U. S. A., 107, 13794, 10.1073/pnas.1008684107

Cornel, 2020, MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy, Cancers (Basel), 12, 10.3390/cancers12071760

Castro, 2018, Interferon-gamma at the crossroads of tumor immune surveillance or evasion, Front. Immunol., 9, 847, 10.3389/fimmu.2018.00847

Chew, 2019, DUX4 suppresses MHC class I to promote cancer immune evasion and resistance to checkpoint blockade, Dev. Cell, 50, 10.1016/j.devcel.2019.06.011

Xi, 2006, Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis, J. Natl. Cancer Inst., 98, 10.1093/jnci/djj020

Ivanov, 2007, Hypoxic repression of STAT1 and its downstream genes by a pVHL/HIF-1 target DEC1/STRA13, Oncogene, 26, 802, 10.1038/sj.onc.1209842

Heinhuis, 2019, Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors, Ann. Oncol., 30, 219, 10.1093/annonc/mdy551

Spiotto, 2016, The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications, Sci. Immunol., 1, 10.1126/sciimmunol.aag1266

Wan, 2012, Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells, PLoS One, 7

Reits, 2006, Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, J. Exp. Med., 203, 1259, 10.1084/jem.20052494

Formenti, 2018, Radiotherapy induces responses of lung cancer to CTLA-4 blockade, Nat. Med., 24, 1845, 10.1038/s41591-018-0232-2

Jiang, 2020, cGAS-STING, an important pathway in cancer immunotherapy, J. Hematol. Oncol., 13, 81, 10.1186/s13045-020-00916-z

Sun, 2017, The non-canonical NF-κB pathway in immunity and inflammation, Nat. Rev. Immunol., 17, 545, 10.1038/nri.2017.52

Lorenzi, 2012, IRF1 and NF-kB Restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma, PLoS One, 7, 10.1371/journal.pone.0046928

Spel, 2018, Nedd4-binding protein 1 and TNFAIP3-interacting protein 1 control MHC-1 display in neuroblastoma, Cancer Res., 78, 10.1158/0008-5472.CAN-18-0545

Chen, 2015, TGF-β and EGF induced HLA-I downregulation is associated with epithelial-mesenchymal transition (EMT) through upregulation of snail in prostate cancer cells, Mol. Immunol., 65, 34, 10.1016/j.molimm.2014.12.017

Brea, 2016, Kinase regulation of human MHC class I molecule expression on cancer cells, Cancer Immunol. Res., 4, 936, 10.1158/2326-6066.CIR-16-0177

He, 2013, The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer, J. Int. Med. Res., 41, 10.1177/0300060513489801

Mimura, 2014, Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-γ treatment, Cancer Sci., 105, 1236, 10.1111/cas.12503

Mimura, 2013, The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer, J. Immunol., 191, 6261, 10.4049/jimmunol.1301597

Kang, 2019, Inhibition of MEK with trametinib enhances the efficacy of anti-PD-L1 inhibitor by regulating anti-tumor immunity in head and neck squamous cell carcinoma, Oncoimmunology., 8, 10.1080/2162402X.2018.1515057

Oh, 2019, ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome, Cancer Immunol. Res., 7, 1984, 10.1158/2326-6066.CIR-19-0056

Herrmann, 2004, HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway, Cancer Res., 64, 10.1158/0008-5472.CAN-2522-2

Maruyama, 2010, Inverse correlation of HER2 with MHC class I expression on oesophageal squamous cell carcinoma, Br. J. Cancer, 103, 552, 10.1038/sj.bjc.6605772

Inoue, 2012, Expression of MHC class I on breast cancer cells correlates inversely with HER2 expression, Oncoimmunology, 1, 1104, 10.4161/onci.21056

Srivastava, 2015, STAT1-induced HLA class I upregulation enhances immunogenicity and clinical response to anti-EGFR mAb cetuximab therapy in HNC patients, Cancer Immunol. Res., 3, 936, 10.1158/2326-6066.CIR-15-0053

Goel, 2017, CDK4/6 inhibition triggers anti-tumour immunity, Nature, 548, 471, 10.1038/nature23465

Versteeg, 1988, c-myc down-regulates class I HLA expression in human melanomas, EMBO J., 7, 1023, 10.1002/j.1460-2075.1988.tb02909.x

Griffioen, 1995, C-myc represses transiently transfected HLA class I promoter sequences not locus-specifically, Immunobiology., 193, 238, 10.1016/S0171-2985(11)80549-8

Michelakos, 2021, Tumor microenvironment immune response in pancreatic ductal adenocarcinoma patients treated with neoadjuvant therapy, J. Natl. Cancer Inst., 13, 182, 10.1093/jnci/djaa073

Yamamoto, 2020, Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I, Nature, 581, 100, 10.1038/s41586-020-2229-5

Li, 2010, Autophagy facilitates major histocompatibility complex class I expression induced by IFN-γ in B16 melanoma cells, Cancer Immunol. Immunother., 59, 313, 10.1007/s00262-009-0752-1

Zeh, 2020, A randomized phase II preoperative study of autophagy inhibition with high-dose hydroxychloroquine and gemcitabine/Nab-paclitaxel in pancreatic cancer patients, Clin. Cancer Res., 26, 3126, 10.1158/1078-0432.CCR-19-4042

Liu, 2020, Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer, Nature, 588, 693, 10.1038/s41586-020-2911-7

Naslavsky, 2004, Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements, Mol. Biol. Cell, 15, 3542, 10.1091/mbc.e04-02-0151

Kulkarni, 2011, Differential microRNA regulation of HLA-C expression and its association with HIV control, Nature, 472, 495, 10.1038/nature09914

Lazaridou, 2020, Identification of microRNAs targeting the transporter associated with antigen processing TAP1 in melanoma, J. Clin. Med., 9, 2690, 10.3390/jcm9092690

Mari, 2018, microRNA 125a Regulates MHC-I Expression on Esophageal Adenocarcinoma Cells, Associated With Suppression of Antitumor Immune Response and Poor Outcomes of Patients, Gastroenterology, 155, 784, 10.1053/j.gastro.2018.06.030

Liu, 2020, miR-451a is downregulated and targets PSMB8 in prostate cancer, Kaohsiung J. Med. Sci., 36, 494, 10.1002/kjm2.12196

Zhao, 2015, MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3, Mol. Med. Rep., 12, 3923, 10.3892/mmr.2015.3826

Kim, 2015, miR-330-5p inhibits proliferation and migration of keratinocytes by targeting Pdia3 expression, FEBS J., 282, 4692, 10.1111/febs.13523

Zhao, 2018, Enhanced MiR-711 transcription by PPARγ induces endoplasmic reticulum stress-mediated apoptosis targeting calnexin in rat cardiomyocytes after myocardial infarction, J. Mol. Cell. Cardiol., 118, 36, 10.1016/j.yjmcc.2018.03.006

Colangelo, 2016, Proteomic screening identifies calreticulin as a miR-27a direct target repressing MHC class I cell surface exposure in colorectal cancer, Cell Death Dis., 7, 10.1038/cddis.2016.28

Belmont, 2012, Regulation of microRNA expression in the heart by the ATF6 branch of the ER stress response, J. Mol. Cell. Cardiol., 52, 1176, 10.1016/j.yjmcc.2012.01.017

Li, 2016, miR-34a and its novel target, NLRC5, are associated with HPV16 persistence, Infect. Genet. Evol., 44, 293, 10.1016/j.meegid.2016.07.013

Ludigs, 2015, NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module, PLoS Genet., 11, 10.1371/journal.pgen.1005088

Hu, 2020, MiR34a Regulates Neuronal MHC Class I Molecules and Promotes Primary Hippocampal Neuron Dendritic Growth and Branching, Front. Cell. Neurosci., 14, 573208, 10.3389/fncel.2020.573208

Pfizenmaier, 1987, Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells, J. Immunol., 138, 975, 10.4049/jimmunol.138.3.975

Johnson, 2003, Locus-specific constitutive and cytokine-induced HLA class I gene expression, J. Immunol., 170, 1894, 10.4049/jimmunol.170.4.1894

Hu, 2020, IL-2 enhanced MHC class I expression in papillary thyroid cancer with Hashimoto’s thyroiditis overcomes immune escape in vitro, J. Cancer, 11, 4250, 10.7150/jca.38330

Yue, 1999, IL-12 directly up-regulates the expression of HLA class I, HLA class II and ICAM-1 on human melanoma cells: a mechanism for its antitumor activity?, Eur. J. Immunol., 29, 1762, 10.1002/(SICI)1521-4141(199906)29:06<1762::AID-IMMU1762>3.0.CO;2-F

Carbotti, 2017, IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient small cell lung cancer cells, J. Exp. Clin. Cancer Res., 36, 140, 10.1186/s13046-017-0608-z

Moreau, 1999, IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes, Int. Immunol., 11, 803, 10.1093/intimm/11.5.803

Lu, 2020, IL-10 restores MHC class I expression and interferes with immunity in papillary thyroid cancer with Hashimoto thyroiditis, Endocrinology, 161, 10.1210/endocr/bqaa062

Maggs, 2020, Improving the clinical significance of preclinical immunotherapy studies through incorporating tumor microenvironment-like conditions, Clin. Cancer Res., 26, 4448, 10.1158/1078-0432.CCR-20-0358

Pouysségur, 2006, Hypoxia signalling in cancer and approaches to enforce tumour regression, Nature., 441, 437, 10.1038/nature04871

Sethumadhavan, 2017, Hypoxia and hypoxia-inducible factor (HIF) downregulate antigen-presenting MHC class I molecules limiting tumor cell recognition by T cells, PLoS One, 12, 10.1371/journal.pone.0187314

Pellegatti, 2008, Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase, PLoS One, 3, 10.1371/journal.pone.0002599

Kim, 2018, Cancer energy metabolism: shutting power off cancer factory, Biomol. Ther. (Seoul), 26, 39, 10.4062/biomolther.2017.184

Schmitt, 2002, Structure and mechanism of ABC transporters, Curr. Opin. Struct. Biol., 12, 754, 10.1016/S0959-440X(02)00399-8

Chan, 2019, Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic, Ann. Oncol., 30, 44, 10.1093/annonc/mdy495

Plesca, 2020, Characteristics of tumor-infiltrating lymphocytes prior to and during immune checkpoint inhibitor therapy, Front. Immunol., 11, 364, 10.3389/fimmu.2020.00364

Gubin, 2014, Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens, Nature, 515, 577, 10.1038/nature13988

Miller, 2015, The journey from discoveries in fundamental immunology to cancer immunotherapy, Cancer Cell, 27, 439, 10.1016/j.ccell.2015.03.007

Kalbasi, 2020, Tumour-intrinsic resistance to immune checkpoint blockade, Nat. Rev. Immunol., 20, 25, 10.1038/s41577-019-0218-4

Donia, 2017, Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNγ signaling, Cancer Res., 77, 4562, 10.1158/0008-5472.CAN-16-3172

Aptsiauri, 2018, The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses, Curr. Opin. Immunol., 51, 123, 10.1016/j.coi.2018.03.006

Rodig, 2018, MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma, Sci. Transl. Med., 10, 10.1126/scitranslmed.aar3342

Ladányi, 2020, Role of the anatomic site in the association of HLA class I antigen expression level in metastases with clinical response to ipilimumab therapy in patients with melanoma, J. Immunother. Cancer, 8, 10.1136/jitc-2019-000209

Cummings, 2020, Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44, Nat. Cancer, 1, 1167, 10.1038/s43018-020-00140-1

Raffaghello, 2005, Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications, Oncogene, 24, 4634, 10.1038/sj.onc.1208594

Deng, 2014, Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice, J. Clin. Invest., 124, 687, 10.1172/JCI67313

Gong, 2018, Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination, J. Immunother. Cancer, 6, 46, 10.1186/s40425-018-0361-7

Mizukami, 2008, Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma, Br. J. Cancer, 99, 1462, 10.1038/sj.bjc.6604715

Wang, 1999, Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells, J. Exp. Med., 190, 205, 10.1084/jem.190.2.205

Tripathi, 2016, Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome, Proc. Natl. Acad. Sci. U. S. A., 113, E1555, 10.1073/pnas.1521812113

Kalaora, 2020, Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma, Nat. Commun., 11, 896, 10.1038/s41467-020-14639-9